May 28, 2017

Reports Making Cryptogenic Strokes a National Health Priority Include Strokes from Atrial Fibrillation

The cause cannot be pinpointed in 25–30 per cent of strokes. Many of these strokes, called cryptogenic strokes, are due to undiagnosed atrial fibrillation, which increases the risk of stroke by 500%. StopAfib.org participated in a conference convened by the American Heart Association to make cryptogenic strokes a national health priority, and we participated in […]

For the 9th Annual Atrial Fibrillation Month, StopAfib.org Raises Awareness, Educates, and Names Medical Advisors

For the 9th annual Atrial Fibrillation Awareness Month, StopAfib.org was part of a collaboration with American Heart Association to raise awareness of afib through a billboard spot in Times Square. We also named new members to our Global Medical Advisory Board and have been publishing the videos from our 2015 National Atrial Fibrillation Patient Conference. […]

Announcing MyAFibExperience.org, from American Heart Association/American Stroke Association and StopAfib.org

My AFib Experience™ (www.myafibexperience.org) is an innovative and unique online community that can help people understand atrial fibrillation, learn how to better manage it, and connect with others who also experience it. A collaboration of the American Heart Association/American Stroke Association and StopAfib.org, with support from Janssen Pharmaceuticals, Inc., MyAFibExperience is designed to help people […]

Dr. Matthew Reynolds on Quality of Life From AF Ablation vs. Antiarrhythmic Drugs — Video

In this video, Dr. Matthew Reynolds, of the Harvard Clinical Research Institute, discussed his quality of life findings from use of catheter ablation and antiarrhythmic drugs for treatment of atrial fibrillation. He analyzed quality of life data that was collected as part of the THERMOCOOL catheter trial in which catheter ablation was found to be […]

Dr. Ken Ellenbogen Talks about Fish Oil for Atrial Fibrillation and Stroke Prevention Drugs — Video

In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs […]